Analysis of cardiac energy metabolism in valve disease using 31P-MR- spectroscopy;Untersuchungen des kardialen energiestoffwechsels bei herzvitien mit der 31P-MR-spektroskopie

Radiologe

Volumn 40, Issue 2, 2000, Pages 162-167

  Beer, M ^a   Viehrig, M ^b   Seyfarth, T ^b   Sandstede, J ^b   Lipke, C ^b   Pabst, T ^b   Kenn, W ^b   Harre, K ^b   Horn, M ^b   Landschutz W ^b   Von Kienlin, M ^b   Neubauer, S ^b   Hahn, D ^b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b NONE

Author keywords

31P MR spectroscopy; Energy metabolism; MR imaging; Valve disease; Valve replacement

Indexed keywords

ADENOSINE TRIPHOSPHATE; CREATINE PHOSPHATE; PHOSPHORUS 31;

ADULT; AORTA VALVE REPLACEMENT; AORTA VALVE STENOSIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; ENERGY CONSUMPTION; EVALUATION; FEMALE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE METABOLISM; HUMAN; IMAGE ANALYSIS; MALE; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; TISSUE LEVEL; TREATMENT OUTCOME;

EID: 17144459595     PISSN: 0033832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001170050026     Document Type: Article

References (30)

1. Auffermann W, Chew W, Wolfe CL, Tavares NJ, Parmley WW, Semelka RC, Donnelly T, Chatterjee K, Higgins CB (1991) Normal and diffusely abnormal myocardium in humans: functional and metabolic characterization with P-31 MR spectroscopy and cine MR imaging. Radiology 179:253-259
2. 31P-MR-Spektroskopie. Rofo Fortschr Geb Roentgenstr Neuen Bildgeb Verfahr 171:65-68
3. Bottomley PA (1994) MR-spectroscopy of the human heart: the status and the challenges. Radiology 191:593-612
4. Bottomley PA, Hardy CJ (1992) Proton Overhauser enhancements in human cardiac phosphorus NMR spectroscopy at 1.5 T. Magn Reson Med 24:384-390
5. 1 values. Magn Reson Med 32:137-141
6. Bottomley PA, Hardy CJ, Roemer PB (1990) Phosphate metabolite imaging and concentration measurements in human heart by nuclear magnetic resonance. Magn Reson Med 14:425-434
7. Bottomley PA, Atalar E, Weiss RG (1996) Human cardiac high-energy phosphate metabolite concentrations by 1D-resolved NMR spectroscopy. Magn Reson Med 35:664-670
8. 31P magnetic resonance spectroscopy. Lancet 338:973-976
9. Conway MA, Bottomley PA, Ouwerkerk R, Radda GK, Rajagopalan B (1998) Mitral regurgitation. Impaired systolic function, eccentric hypertrophy, and increased severity are linked to lower phosphocreartine/ATP ratios in humans. Circulation 97:1716-1723
10. Ingwall JS, Kramer MF, Fifer MA, Lorell BH, Shemin R, Grossman W, Allen PD (1985) The creatine kinase system in normal and diseased myocardium. N Engl J Med 313:1050-1054
11. Janati-Idrissi R, Besson B, Laplace M, Bui MH (1995) In situ mitochondrial function in volume-overload- and pressure overload-induced cardiac hypertrophy in rats. Basic Res Cardiol 90:305-313
12. Kennedy JW, Doces J, Steward DK (1977) Left ventricular function before and following aortic valve replacement. Circulation 56:944-950
13. 31P-MR-spectroscopy. Proc Int Soc Magn Reson Med 7:1497
14. Lamb HJ, Beyerbracht HP, Laarse A van der, Stoel BC, Doornbos J, Wall EE van der, Roos A de (1999) Diastolic dysfunction in hypertensive heart disease is associated with altered myocardial metabolism. Circulation 99:2261-2267
15. 31P MRS in humans. J Magn Reson 134:287-299
16. 31P NMR spectroscopy. Magn Reson Med 41:657-663
17. Monrad ES, Hess OM, Murakami T, Nonogi H, Corin WJ, Krayenbuehl HP (1988) Time course of regression of left ventricular hypertrophy after aortic valve replacement. Circulation 77:1345-1355
18. Nascimben L, Ingwall JS, Pauletto P, Friedrich J, Gwathmey JK, Saks V, Pessina AC, Allen PD (1996) The creatine kinase system in failing and nonfailing human myocardium. Circulation 94:1894-1901
19. Neubauer S (1999) Magnetic resonance spectroscopy for the non-invasive evaluation of cardiac metabolism. In: Bogart J, Duerinckx AJ, Rademakers F (eds) Clinical applications of MRI in cardiovascular disease. Springer, Heidelberg New York
20. 31P magnetic resonance spectroscopy in dilated cardiomyopathy and coronary artery disease. Altered cardiac high-energy phosphate metabolism in heart failure. Circulation 86:1810-1818
21. 31P-magnetic resonance spectroscopy. J Invest Med 45:453-462
22. Neubauer S, Horn M, Cramer M, Harre K, Newell JB, Peters W, Pabst T, Ertl G, Hahn D, Ingwall JS, Kochsiek K (1997) In patients with dilated cardiomyopathy the myocardial phosphocreatine-to-ATP ratio is a predictor of mortality. Circulation 96:2190-2196
23. Otto CM, Kuusisto J, Reichenbach DD, Gown AM, O'Brien KD (1994) Characterization of the early lesion of "degenerative" valvular aortic stenosis: histological and immunohistochemical studies. Circulation 90:844-853
24. Peyton RB, Jones RN, Attarian D, Sink JD, Trigt P van, Currie WD, Wechsler AS (1982) Depressed high-energy phosphate content in hypertrophied ventricles of animal and man. Ann Surg 196:278-284
25. Sandstede J, Lipke C, Beer M, Pabst T, Kenn W, Neubauer S, Hahn D (in press) Age- and gender-dependent differences of left and right ventricular cardiac function and mass determined by cine MR imaging. Eur Radiol, in press
26. Swain JL, Sabina RL, Peyton RB, Jones RN, Wechsler AS, Holmes EW (1982) Derangements in myocardial purine and pyrimidine nucleotide metabolism in patients with coronary artery disease and left ventricular hypertrophy. Proc Natl Acad Sci USA 79:655-659
27. Taniguchi K, Nakano S, Kawashima Y, Sakei K, Kawamoto T, Sakahi S, Kobayashi J, Morimoto S, Matsuda H (1990) Left ventricular ejection performance, wall stress, and contractile state in aortic regurgitation before and after aortic valve replacement. Circulation 82:798-807
28. Von Kienlin M, Mejia R (1991) Spectral localization with optimal pointspread function. J Magn Reson 94:268-287
29. Zhang J, Merkle H, Hendrich K, Garwood M, From AH, Ugurbil K, Bache RJ (1993) Bioenergetic abnormalities associated with severe left ventricular hypertrophy. J Clin Invest 92:993-1003
30. 31P-NMR spectroscopic study. Circulation 92:1274-1283